Search results for "Lipoproteins."

showing 10 items of 492 documents

Estradiol, acting through estrogen receptor alpha, restores dimethylarginine dimethylaminohydrolase activity and nitric oxide production in oxLDL-tre…

2011

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide (NO) synthase. ADMA accumulation, mainly due to a decreased dimethylarginine dimethylaminohydrolase (DDAH) activity, has been related to the development of cardiovascular diseases. We investigate whether estradiol prevents the changes induced by oxidized low density lipoprotein (oxLDL) on the DDAH/ADMA/NO pathway in human umbilical artery endothelial cells (HUAEC). HUAEC were exposed to estradiol, native LDL (nLDL), oxLDL and their combinations for 24 h. In some experiments, cells were also exposed to the unspecific estrogen receptor (ER) antagonist ICI 182780, the specific ERα antagonist MPP or specific agonists …

medicine.medical_specialtyProtein-Arginine N-MethyltransferasesEndotheliumNitric Oxide Synthase Type IIImedicine.drug_classBlotting WesternArginineNitric OxideBiochemistryUmbilical ArteriesNitric oxideAmidohydrolasesReceptors G-Protein-Coupledchemistry.chemical_compoundEndocrinologyEnosInternal medicinemedicineEstrogen Receptor betaHumansEstrogens Non-SteroidalMolecular BiologyCells CulturedbiologyEstradiolArtèriesProtein StabilityEstrogen AntagonistsEstrogen Receptor alphaEndoteli vascularbiology.organism_classificationNitric oxide synthaseIsoenzymesLipoproteins LDLRepressor Proteinsmedicine.anatomical_structureEndocrinologychemistryReceptors EstrogenEstrogenbiology.proteinlipids (amino acids peptides and proteins)Endothelium VascularAsymmetric dimethylarginineEstrogen receptor alphaGPER
researchProduct

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retr…

2021

Abstract Background Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis (LA). Lomitapide is an emerging therapy in HoFH, but its place in the treatment algorithm is disputed because a comparison of its long-term efficacy versus LA in reducing LDL-C burden is not available. We assessed changes in long-term LDL-C burden and goals achievement in two independent HoFH patients’ cohorts, one treated with lomitapide in Ita…

medicine.medical_specialtySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]LipoproteinsGenetic diseaseTherapeuticsFamilial hypercholesterolemiaDiseaseLipoprotein apheresiLDLHyperlipoproteinemia Type IIchemistry.chemical_compoundLipoprotein apheresisRetrospective surveyInternal medicineCholesterol burden; Genetic disease; Homozygous hypercholesterolemia; LDL; Lipoprotein apheresis; Lomitapide; Therapeutics; Benzimidazoles; Homozygote; Humans; Lipoproteins; Retrospective Studies; Anticholesteremic Agents; Blood Component Removal; Hyperlipoproteinemia Type IImedicineHumansPharmacology (medical)Genetics (clinical)Retrospective Studiesmedicine.diagnostic_testbusiness.industryResearchAnticholesteremic AgentsHomozygous hypercholesterolemiaHomozygoteRGeneral Medicinemedicine.diseaseLomitapideLomitapidecholesterol burden; genetic disease; homozygous hypercholesterolemia; LDL; lipoprotein apheresis; lomitapide; therapeuticsCholesterol burdenchemistryCohortBlood Component RemovalMedicineTherapeutics.BenzimidazolesLipid profilebusinessLipoprotein apheresisCross nationalOrphanet Journal of Rare Diseases
researchProduct

Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?

2005

The term "lipid triad" or "atherogenic lipoprotein phenotype" has been introduced to describe a common form of dyslipidemia, characterized by three lipid abnormalities: increased plasma triglyceride levels, decreased HDL-cholesterol concentrations and the presence of small, dense LDL particles. It has been suggested that the clinical importance of the atherogenic lipoprotein phenotype probably exceeds that of LDL-cholesterol, because many more patients with coronary artery disease are found to have this trait than hypercholesterolaemia. There is a body of evidence that therapies effective against plasma HDL-cholesterol and triglycerides are associated with a strong reduction of cardiovascul…

medicine.medical_specialtySmall dense ldlBiologyCoronary artery diseaseCardiovascular preventionInternal medicineInternal MedicinemedicineHumansNational Cholesterol Education ProgramDyslipidemiasHypolipidemic AgentsLDL HDL triglycerides preventionBiochemistry (medical)LDL Particle SizeTriad (anatomy)Atherogenic lipoprotein phenotypemedicine.diseaseAtherosclerosisLipoproteins LDLEndocrinologymedicine.anatomical_structureCardiovascular Diseaseslipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineDyslipidemiaJournal of atherosclerosis and thrombosis
researchProduct

The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates

2007

Beyond total low-density-lipoproteins (LDL) levels, increasing evidence suggests that the 'quality' of LDL exerts a great influence on the cardiovascular risk. Several studies have also shown that the therapeutic modulation of LDL size is of benefit in reducing the risk of cardiovascular events. Hypolipidaemic treatment is able to alter LDL subclass distribution but strong variations have been noticed among different agents. Fibrates have a major impact on triglyceride metabolism and in modulating LDL size and subclasses, but variations exist among the different molecules.A literature search (by Medline and Scopus) was performed using the following headings: 'small dense LDL', 'LDL size', '…

medicine.medical_specialtySmall dense ldlClofibric AcidFenofibrateInternal medicinemedicineLow densityHumansGemfibrozilClinical significanceParticle SizeDyslipidemiasHypolipidemic AgentsBezafibrateFenofibratebusiness.industryBezafibrateDense low density lipoproteinFenofibrate Gemfibrozil Subfractions TherapyLdl subfractionsFibric AcidsGeneral MedicineLipoproteins LDLTreatment OutcomeEndocrinologylipids (amino acids peptides and proteins)CiprofibrateBezafibrateGemfibrozilbusinessmedicine.drug
researchProduct

Should we measure routinely the LDL peak particle size?

2004

Low density lipoproteins (LDL) do not show in humans a normal distribution and comprise two different main fractions: large, buoyant (phenotype pattern A) and small, dense (phenotype pattern B) particles, that differ not only in size and density but also in physicochemical composition, metabolic behaviour and atherogenicity. The prevalence of small, dense LDL changes with age (30-35% in adult men, 5-10% in men <20 years and in pre-menopausal women, 15-25% in postmenopausal women) and is genetically influenced, with a heritability ranging from 35% to 45%. Small, dense LDL correlate negatively with plasma HDL levels and positively with plasma triglyceride levels and are associated with the me…

medicine.medical_specialtySmall dense LDLAcute myocardial infarctionCoronary artery diseaseRisk FactorsDiabetes mellitusInternal medicineDiabetes MellitusmedicineHumansMyocardial infarctionParticle SizeRisk factorNational Cholesterol Education ProgramTriglyceridesMetabolic Syndromebusiness.industryVascular diseasePreventionmedicine.diseaseLipoproteins LDLCoronary heart diseasePhenotypeCardiovascular DiseasesAtherosclerosiCirculatory systemCardiologylipids (amino acids peptides and proteins)Metabolic syndromeLipoproteins HDLCardiology and Cardiovascular Medicinebusiness
researchProduct

An Update on the Role of the Quality of LDL in Cardiovascular Risk:The Contribution of the Universities of Palermo and Zurich

2007

Low density lipoproteins (LDL) size seems to be an important predictor of cardiovascular events and progression of coronary artery disease and the predominance of small dense LDL have been accepted as an emerging cardiovascular risk factor by the National Cholesterol Education Program Adult Treatment Panel III. We recently showed increased LDL size or higher levels of small, dense LDL in different categories of patients at higher cardiovascular risk, such as those with coronary (including acute myocardial infarction) and non-coronary (including carotid disease, abdominal aortic aneurysm and peripheral arterial disease) forms of atherosclerosis or metabolic diseases (including type-II diabet…

medicine.medical_specialtyStatinUniversitiesmedicine.drug_classCoronary artery diseaseEzetimibeInternal medicineDrug DiscoverymedicineHumansPharmacology (medical)RosuvastatinCholesterol absorption inhibitorParticle SizeRisk factorNational Cholesterol Education Programbusiness.industrymedicine.diseasePolycystic ovaryLipoproteins LDLItalyCardiovascular DiseasesCardiologylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessSwitzerlandmedicine.drugRecent Patents on Cardiovascular Drug Discovery
researchProduct

In vitro free radical scavenging capacity of thyroid hormones and structural analogues.

2001

It was reported that thyroid hormones decreased Cu(2+)-induced low-density lipoprotein (LDL) oxidation in vitro. Here, we investigated free radical scavenging capacities of thyroid hormones (3,5,3'-tri-iodo-L-thyronine (T(3)), thyroxine (T(4)) and 3,3',5'-tri-iodo-L-thyronine (rT(3))) and structural analogues (L-thyronine (T(0)), 3,5,3'tri-iodothyroacetic acid (TA(3)) and 3,5,3',5'-tetra-iodothyroacetic acid (TA(4))), using three different models of free radical generation. T(0), T(3) and TA(3) slowed down production of conjugated diene and thiobarbituric acid-reactive substances during LDL oxidation by 2,2'-azobis-[2-amidinopropane] (water-soluble), whereas rT(3), T(4) and TA(4) had practi…

medicine.medical_specialtyThyroid HormonesTriiodothyronine ReverseEndocrinology Diabetes and MetabolismRadicalMedicinal chemistryThiobarbituric Acid Reactive Substanceschemistry.chemical_compoundEndocrinologyInternal medicinemedicineHumansOxidase testAnalysis of VarianceTriiodothyronineSuperoxideThyroidElectron Spin Resonance SpectroscopyFree Radical ScavengersThiobarbituratesIn vitroLipoproteins LDLThyroxinemedicine.anatomical_structureEndocrinologychemistryBiochemistryTriiodothyronineOxidation-ReductionHormoneLipoproteinThe Journal of endocrinology
researchProduct

Involvement of Oxysterols and Lysophosphatidylcholine in the Oxidized LDL–Induced Impairment of Serum Albumin Synthesis by HEPG2 Cells

2000

Abstract —Oxidized low density lipoproteins (Ox-LDLs) are increasingly thought to be a key element in atherogenesis. We have previously reported that serum albumin has important antioxidant properties and that a reduced synthesis of albumin may represent a crucial point in the overall antioxidant defense. In the present work, we aimed at determining whether Ox-LDL could modulate albumin synthesis in cultured human hepatocytes (HepG2 cells). With the use of enzyme immunoassay and radiolabeled leucine incorporation followed by specific immunoprecipitation, Ox-LDL was found to lead to a dose-dependent decrease in albumin secretion. Moreover, the protein synthesis and mRNA levels were decrease…

medicine.medical_specialtyTime FactorsAntioxidantmedicine.medical_treatmentHypercholesterolemiaSerum albuminDown-RegulationTritiumAntioxidantsLipid peroxidationchemistry.chemical_compoundLeucineInternal medicineDiabetes MellitusTumor Cells CulturedmedicineHumansRNA MessengerKetocholesterolsSerum AlbuminDose-Response Relationship DrugbiologyChemistryAlbuminLysophosphatidylcholinesBiological activityHydroxycholesterolsIn vitroLipoproteins LDLEndocrinologyLysophosphatidylcholinemedicine.anatomical_structureGene Expression RegulationLiverBiochemistryHepatocytebiology.proteinlipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

Serum sphingomyelin levels are related to the clearance of postprandial remnant-like particles.

2005

It is known that sphingomyelin (SM) content is higher in apolipoprotein B-containing particles (BLps) than in high density lipoproteins and that BLp levels, including chylomicrons and their remnant particles, are positively related to atherosclerosis. To evaluate the relationship between serum SM and postprandial remnant particle levels, we determined SM, triglyceride (TG), and cholesterol levels in serum and in remnant-like particles (RLPs) before and 3, 5, 7, and 10 h after a high-fat meal in 31 healthy subjects. We found that serum SM, like serum TG, was increased to its maximum 3 h after fat loading and then gradually decreased to basal levels after 10 h. More important, we determined t…

medicine.medical_specialtyTime FactorsApolipoprotein BArteriosclerosisQD415-436Biochemistrychemistry.chemical_compoundEndocrinologylipidInternal medicineChylomicronsmedicineHumansTriglyceridesApolipoproteins BbiologyTriglycerideCholesterollipoproteinCholesterol HDLCell BiologyArteriosclerosismedicine.diseasePostprandial PeriodSphingomyelinsEndocrinologyPostprandialCholesterolchemistrybiology.proteinatherosclerosisSphingomyelinLipoproteins HDLBiomarkersChylomicronLipoproteinJournal of lipid research
researchProduct

Differential effects of oxidized LDL on apolipoprotein AI and B synthesis in HepG2 cells

2006

Oxidized low-density lipoproteins (Ox-LDL) are key elements in atherogenesis. Apolipoprotein AI (apoAI) is an active component of the antiatherogenic high-density lipoproteins (HDL). In contrast, plasma apolipoprotein B (apoB), the main component of LDL, is highly correlated with coronary risk. Our results, obtained in HepG2 cells, show that Ox-LDL, unlike native LDL, leads to opposite effects on apoB and apoAI, namely a decrease in apoAI and an increase in apoB secretion as evaluated by [(3)H]leucine incorporation and specific immunoprecipitation. Parallel pulse-chase studies show that Ox-LDL impaired apoB degradation, whereas apoAI degradation was increased and mRNA levels were decreased.…

medicine.medical_specialtyTime FactorsFree RadicalsApolipoprotein BImmunoprecipitationBiochemistryCell Linechemistry.chemical_compoundLeucinePhysiology (medical)Lipid biosynthesisInternal medicinemedicineHumansSecretionRNA MessengerTriglyceridesGlyceraldehyde 3-phosphate dehydrogenaseApolipoproteins BApolipoprotein A-IbiologyCholesterolnutritional and metabolic diseasesAtherosclerosisLipidsMOPSLipoproteins LDLOxygenEndocrinologychemistryCell culturebiology.proteinlipids (amino acids peptides and proteins)Cholesterol EstersFree Radical Biology and Medicine
researchProduct